Evaxion biotech a/s announces executive management changes

Copenhagen, denmark, aug. 02, 2022 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage biotechnology company specializing in the development of ai-driven immunotherapies, today announced the following executive management changes. lars staal wegner has decided to resign as the company's chief executive officer (ceo). dr. wegner will remain with the company in an advisory role to the company's new ceo and board of directors.
EVAX Ratings Summary
EVAX Quant Ranking